|
|
Blood, 1 March 2007, Vol. 109, No. 5, pp. 1931-1937.
Prepublished online as a Blood First Edition Paper on November 2, 2006; DOI 10.1182/blood-2006-07-037283.
Previous Article | Next Article 
Submitted July 25, 2006
Accepted October 22, 2006
Active tissue factor pathway inhibitor is expressed on the surface of coated-platelets
Susan A Maroney, Sandra L Haberichter, Paul Friese, Maureen L Collins, Josephine P Ferrel, George L Dale, and Alan E Mast*
Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI
Dept of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
Dept of Medicine, University of Oklahoma School of Medicine, Oklahoma City, OK
* Corresponding author; email: alan.mast{at}bcw.edu.
The incorporation of blood borne forms of tissue factor (TF) into a growing blood clot is necessary for normal fibrin generation and stabilization of the blood clot. Tissue factor pathway inhibitor (TFPI) is the primary physiological inhibitor of tissue factor and is present within platelets. Expression of TFPI on the platelet surface may be the optimal location for it to abrogate blood borne TF activity that incorporates within the blood clot; balancing the need for adequate hemostasis while preventing development of occlusive thrombosis. TFPI is produced by megakaryocytes but is not expressed on the platelet surface. Activation of platelets thrombin receptor activation peptide does not cause release or surface expression of TFPI, demonstrating that TFPI is not stored within platelet -granules. TFPI is expressed on the platelet surface following dual agonist activation with convulxin plus thrombin to produce coated-platelets. In association with its expression on the surface of coated-platelets TFPI is also released in microvesicles or as a soluble protein.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Duckers, P. Simioni, L. Spiezia, C. Radu, S. Gavasso, J. Rosing, and E. Castoldi
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
Blood,
November 1, 2008;
112(9):
3615 - 3623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T.B. Crawley and D. A. Lane
The Haemostatic Role of Tissue Factor Pathway Inhibitor
Arterioscler Thromb Vasc Biol,
February 1, 2008;
28(2):
233 - 242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Jobe, K. M. Wilson, L. Leo, A. Raimondi, J. D. Molkentin, S. R. Lentz, and J. Di Paola
Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis
Blood,
February 1, 2008;
111(3):
1257 - 1265.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|